← All trials
NCT06878833
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Mar 17, 2025
- Last posted
- Apr 8, 2025
- Enrollment
- 0
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lyndra Inc.Lead sponsor
- Lyndra Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.